Targeted Methylation Biomarker Detection in Cell-Free DNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing DNA methylation status, such as whole genome bisulfite sequencing, have limitations in detecting specific short genomic regions useful as biomarkers for diseases like colorectal cancer, particularly in blood-based samples where signal-to-noise ratios are high and GC content variations affect sequencing data quality.
Innovation Solution
The method involves determining methylation status using next-generation sequencing (NGS) techniques, specifically targeting differentially methylated regions (DMRs) in cell-free DNA, with improved probe design and experimental parameters to enhance GC coverage and data quality, allowing for more accurate detection of methylation biomarkers in blood samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If whole genome bisulfite sequencing (WGBS) is used to analyze genome-wide methylation status, then comprehensive methylation coverage is achieved, but resolution of specific short genomic regions deteriorates
Solution Approach 1:
The patent divides the genome into specific targeted regions of interest (DMRs) rather than analyzing the entire genome. This segmentation allows concentrated sequencing depth and improved resolution on specific genomic regions while reducing overall complexity and cost.
Solution Approach 2:
The patent extracts and focuses on specific differentially methylated regions (DMRs) that are relevant to disease biomarkers, separating these critical regions from the rest of the genome for dedicated analysis. This extraction enables high-resolution study of biomarker regions without being diluted by whole-genome noise.
2Ease of operation
If blood-based samples are used for methylation analysis, then accessibility of sample collection is improved, but signal-to-noise ratio deteriorates
Solution Approach 1:
The patent uses cell-free DNA in plasma as an intermediary that carries methylation information from tumor cells into the bloodstream. This intermediary allows non-invasive sampling while preserving the methylation signal, bridging the gap between easy blood collection and accurate tumor detection.
Solution Approach 2:
The patent analyzes methylation patterns in cell-free DNA that copies the epigenetic signature of tumor cells. This copying approach allows detection of tumor methylation biomarkers through blood samples without directly sampling the tumor tissue, maintaining signal fidelity while improving accessibility.
3Adaptability or versatility
If GC content variations are present in DNA samples, then natural genomic diversity is represented, but sequencing data quality deteriorates
Solution Approach 1:
The patent optimizes sequencing parameters and probe design specifically for GC-rich regions, adjusting temperature, chemistry, and enrichment strategies to maintain reliable data quality across varying GC contents while preserving natural genomic diversity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides higher sensitivity for advanced adenoma detection, with sensitivity rates of at least 54%, and improves data quality by optimizing GC coverage and conversion rates, enabling more accurate identification of methylation biomarkers for colorectal cancer diagnosis.
Implementation Method 1
sodium bisulfite is used to convert unmethylated cytosines into uracil, while methylated forms of cytosine (e.g., 5-methylcytosine and 5-hydroxymethylcytosine) remain unchanged
Data Source
AI summary
The present disclosure provides, among other things, methods for cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal and/or advanced adenoma detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using next-generation sequencing techniques.